Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Rivastigmine tartrate (SDZ-ENA 713) is a carbamate-derived reversible CHOLINESTERASE INHIBITOR that is selective for the CENTRAL NERVOUS SYSTEM and is used for the treatment of DEMENTIA in ALZHEIMER DISEASE and PARKINSON DISEASE.
パッケージサイズ | 在庫状況 | 単価(税別) |
---|---|---|
25 mg | お問い合わせ | ¥ 11,000 |
50 mg | お問い合わせ | ¥ 13,000 |
100 mg | お問い合わせ | ¥ 18,500 |
200 mg | お問い合わせ | ¥ 25,000 |
1 mL * 10 mM (in DMSO) | お問い合わせ | ¥ 13,500 |
説明 | Rivastigmine tartrate (SDZ-ENA 713) is a carbamate-derived reversible CHOLINESTERASE INHIBITOR that is selective for the CENTRAL NERVOUS SYSTEM and is used for the treatment of DEMENTIA in ALZHEIMER DISEASE and PARKINSON DISEASE. |
ターゲット&IC50 | AChR:5.5 μM |
別名 | SDZ-ENA 713, ENA 713 |
分子量 | 400.43 |
分子式 | C14H22N2O2·C4H6O6 |
CAS No. | 129101-54-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ethanol: 74 mg/mL (184.8 mM)
DMSO: 39 mg/mL (97.4 mM)
H2O: 73 mg/mL (182.3 mM)
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Rivastigmine tartrate 129101-54-8 Neuroscience AChR AChE ENA-713 BBB cholinesterase acetylcholinesteras SDZ-ENA 713 BChE disease orally butyrylcholinesterase Inhibitor Alzheimer's Parkinson's SDZ-ENA-713 ENA 713 Cholinesterase (ChE) ENA713 ChE Rivastigmine Tartrate SDZ-ENA713 Rivastigmine cholinergic inhibit parasympathomimetic inhibitor